Market revenue in 2022 | USD 102.5 million |
Market revenue in 2030 | USD 183.0 million |
Growth rate | 7.5% (CAGR from 2022 to 2030) |
Largest segment | Reagents & consumables |
Fastest growing segment | Reagents & Consumables |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Analyzers, Reagents & Consumables |
Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.17% in 2022. Horizon Databook has segmented the Australia thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Technological advancements in biomarker testing related to hemostasis, increasing demand for personalized medicine to treat thrombosis-related conditions, and favorable government initiatives & policies are the key factors driving the market in the country.
The increasing geriatric population and rising chronic disease prevalence are further contributing to market growth. For instance, according to the Australian Institute of Health and Welfare, in June 2020, 4.2 million people in the country were aged 65 years and above, accounting for 16% of the total population.
Some of the key players in Australia’s thrombosis and hemostasis biomarkers market are F. Hoffman-LA Roche AG, Siemens Healthcare, and Bio-Rad-Laboratories, Inc.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Australia thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account